GoAI
Get started
Ironwood Pharmaceuticals, Inc. logo

Ironwood Pharmaceuticals, Inc.

IRWD

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$4.29

+$0.15 · +3.62%

Aug 21, 4:00 PM ET

IRWD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

85

Deep Value

Momentum

74

Gaining

Sentiment

57

Mixed

Risk resilience

54

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Thomas A. McCourt
Listed since
Feb 3, 2010
Employees
100

Market position

Day range

Current $4.29

52-week range

Current $4.29

Open
$4.24
Previous close
$4.14
Volume
2.27M
0.97× average
Average volume
2.35M
Average daily volume
Market cap
706.19M USD
Beta
0.21
Market reference 1
50-day average
$4.0648
+5.54% above average
200-day average
$3.8532
+11.34% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
929.01M USD
P/E (TTM)
5.39×
P/B (TTM)
-4.39×
P/S (TTM)
1.81×
EV / EBITDA
8.88×
Earnings yield
4.39%
Free cash flow yield
23.23%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.76%
Operating margin
60.64%
Net margin
33.36%
Return on equity
-9.17%
Return on assets
6.05%
Return on invested capital
11.39%

Financial health

Debt / equity
-2.45×
Current ratio
1.13×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends163%21%-120%-262%Gross margin, FY2021: 82.98%Gross margin, FY2022: 99.65%Gross margin, FY2023: 98.61%Gross margin, FY2024: 97.85%Gross margin, FY2025: 100.00%Operating margin, FY2021: 56.13%Operating margin, FY2022: 60.97%Operating margin, FY2023: -213.54%Operating margin, FY2024: 26.50%Operating margin, FY2025: 40.10%Net margin, FY2021: 127.72%Net margin, FY2022: 42.64%Net margin, FY2023: -226.37%Net margin, FY2024: 0.25%Net margin, FY2025: 8.11%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 82.98%. Gross margin FY2022 99.65%. Gross margin FY2023 98.61%. Gross margin FY2024 97.85%. Gross margin FY2025 100.00%. Operating margin FY2021 56.13%. Operating margin FY2022 60.97%. Operating margin FY2023 -213.54%. Operating margin FY2024 26.50%. Operating margin FY2025 40.10%. Net margin FY2021 127.72%. Net margin FY2022 42.64%. Net margin FY2023 -226.37%. Net margin FY2024 0.25%. Net margin FY2025 8.11%.

Income trends

Revenue

296.15M USD-15.72%

Operating income

118.76M USD+27.53%

Net income

24.02M USD+2629.20%
Income trends across reported periods681.52M USD69.24M USD−543.03M USD−1.16B USDRevenue, FY2021: 413.75M USDRevenue, FY2022: 410.6M USDRevenue, FY2023: 442.74M USDRevenue, FY2024: 351.41M USDRevenue, FY2025: 296.15M USDOperating income, FY2021: 232.26M USDOperating income, FY2022: 250.34M USDOperating income, FY2023: −945.43M USDOperating income, FY2024: 93.12M USDOperating income, FY2025: 118.76M USDNet income, FY2021: 528.45M USDNet income, FY2022: 175.07M USDNet income, FY2023: −1B USDNet income, FY2024: 880K USDNet income, FY2025: 24.02M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 413.75M USD. Revenue FY2022 410.6M USD. Revenue FY2023 442.74M USD. Revenue FY2024 351.41M USD. Revenue FY2025 296.15M USD. Operating income FY2021 232.26M USD. Operating income FY2022 250.34M USD. Operating income FY2023 −945.43M USD. Operating income FY2024 93.12M USD. Operating income FY2025 118.76M USD. Net income FY2021 528.45M USD. Net income FY2022 175.07M USD. Net income FY2023 −1B USD. Net income FY2024 880K USD. Net income FY2025 24.02M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue296.15M USD351.41M USD442.74M USD410.6M USD413.75M USD
Cost of goods sold—7.55M USD6.15M USD1.42M USD70.41M USD
Gross profit296.15M USD343.86M USD436.59M USD409.18M USD343.35M USD
Research and development95.14M USD111.42M USD116.09M USD44.27M USD70.41M USD
Selling, general, and administrative82.26M USD——115.99M USD—
Operating expenses177.39M USD250.73M USD1.38B USD158.84M USD111.09M USD
Interest income4.08M USD4.47M USD18.97M USD9.5M USD726K USD
Interest expense32.75M USD33.03M USD21.63M USD7.6M USD31.15M USD
Depreciation and amortization1.88M USD2.01M USD1.58M USD1.42M USD1.52M USD
Operating income118.76M USD93.12M USD−945.43M USD250.34M USD232.26M USD
Net income24.02M USD880K USD−1B USD175.07M USD528.45M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
+19.65%
11 comparable reports
Latest EPS result
0.31
Estimate 0.32 · Miss by 3.13%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.360.15-0.06-0.27Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.02, estimate 0.12, surprise -83.33%, Miss. Q2 2025, reported May 7, 2025: actual -0.23, estimate -0.05, surprise -360.00%, Miss. Q3 2025, reported Aug 7, 2025: actual 0.14, estimate -0.02, surprise +800.00%, Beat. Q4 2025, reported Nov 10, 2025: actual 0.24, estimate 0.09, surprise +166.67%, Beat. Q1 2026, reported Feb 25, 2026: actual -0.01, estimate 0.02, surprise -150.00%, Miss. Q2 2026, reported May 7, 2026: actual 0.24, estimate 0.07, surprise +242.86%, Beat. Q3 2026, reported Aug 6, 2026: actual 0.31, estimate 0.32, surprise -3.13%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 0.3, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates128.53M97.35M66.16M34.97MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 90.55M USD, estimate 93.77M USD, surprise -3.44%, Miss. Q2 2025, reported May 7, 2025: actual 41.14M USD, estimate 45.9M USD, surprise -10.36%, Miss. Q3 2025, reported Aug 7, 2025: actual 85.24M USD, estimate 60.78M USD, surprise +40.25%, Beat. Q4 2025, reported Nov 10, 2025: actual 122.06M USD, estimate 74.71M USD, surprise +63.38%, Beat. Q1 2026, reported Feb 25, 2026: actual 47.71M USD, estimate 50.92M USD, surprise -6.30%, Miss. Q2 2026, reported May 7, 2026: actual 106.51M USD, estimate 92.11M USD, surprise +15.63%, Beat. Q3 2026, reported Aug 6, 2026: actual 113.04M USD, estimate 114.84M USD, surprise -1.57%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 119.99M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$3.70

13.75% downside
Past 12 months12-month forecastHigh $3.70Average $3.70Low $3.70

Rating distribution

30 ratings
Strong buy00%
Buy1137%
Hold1653%
Sell310%
Strong sell00%

Recent analyst actions

7 institutions
JefferiesdowngradeBuyHold
Leerink PartnersmaintainMarket Perform
JMP SecuritiesmaintainMarket Outperform
Piper SandlermaintainOverweight

IRWD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IRWD

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
23.9M
Weight
0.21%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
20.23M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
17.38M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
7.01M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Schwab Fundamental U.S. Small Company Index ETF logoSchwab Fundamental U.S. Small Company Index ETFFNDA
Market value
6.76M
Weight
0.07%
AUM
9.26B USD
Expense ratio
0.25%
Price / 1D
$37.73+0.75%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
5.85M
Weight
0.04%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
4.86M
Weight
0.05%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Pacer US Small Cap Cash Cows ETF logoPacer US Small Cap Cash Cows ETFCALF
Market value
4.68M
Weight
0.12%
AUM
3.89B USD
Expense ratio
0.59%
Price / 1D
$57.80+0.87%

Continue in GoAI

Research IRWD

research.disclaimer